Glycomine

Glycomine is a biotechnology company focused on developing replacement therapies for rare genetic diseases. Its lead drug candidate, GLM101, is in clinical trials for the treatment of PMM2-CDG, a rare genetic disease of glycosylation.

Glycomine is a biotechnology company focused on developing new therapies for orphan diseases. The company has received FDA clearance of an Investigational New Drug (IND) application for GLM101 for the treatment of PMM2-CDG and is enrolling participants in a Phase 2b clinical trial. In June 2021, Glycomine announced the publication of a key finding from a natural history study of PMM2-CDG, indicating that patients may be at risk for adrenal insufficiency.

1. Replacement Therapies for Rare Diseases| PMM2-CDG | Glycomine
2. Glycomine’s Natural History Study Informs Potentially Lifesaving Update To Standard Of Care For PMM2-CDG Patients | Glycomine
3. Therapeutics For Serious Rare Diseases | About Glycomine
4. Glycomine Programs PMM2-CDG (CDG-1a) | Drug Development
5. Glycomine